The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 nuclease (Cas9) is an innovative genome editing tool that has recently transformed the arena of human genetic engineering. CRISPR/Cas9 can modulate gene expression in plants, humans, and animals based on an RNA-guided mechanism. The CRISPR/Cas9 programmable nucleases are the preferred choices over traditional genome editing technologies, which is attributable to ease in target design, the facility to target multiple sites in one step, and predictable off-target sites.

The Global CRISPR-CAS9 Gene Editing Technologies Market was valued at USD 1,549.5 Million in 2019, and it is anticipated to reach USD 4,505.7 Million by 2027, growing at a CAGR of 13.5% during the forecast period of 2020-2027.

The technique is being effectively employed in therapeutics development. Large biotech companies like Millipore Sigma (earlier Sigma Aldrich), Thermo Fisher Scientific, Toolgen, Genecopeia, Horizon Discovery, and Agilent Technologies and pharmaceuticals like Novartis, Vertex, Bayer AG, AstraZeneca, Evolva, Juno Therapeutics, and GE Healthcare have invested in the CRISPR novel techniques to evolve their drug discovery and development processes. They are forming strategic alliances with crucial CRISPR technology companies like Crispr Therapeutics, Editas Medicine, Caribou Biosciences and Intellia Therapeutics to devise gene-based therapies for various genetic diseases.

Vendors of these solutions are exploring possibilities of various applications of CRISPR-CAs9 tool in gene therapy have raised more than US$ 500 million. For instance, Bayer and CRISPR Therapeutics collaborated to form a major joint venture Casebia Therapeutics in 2016 to explore possibilities of curing genetic diseases using CRISPR-based tools.

Factors that drive the market growth involves, increasing government funding for genomics projects, increasing application of genomics in medical field, and growing prevalence of infectious and genetic diseases. Additionally, rapid advancement in technology and increasing demand for genetically modified crops has fuelled the growth of the market.

However, gene editing and research is a brainstorming process and requires skilled professionals. Additionally, high cost of research and long approval time for the products may slow the growth of the market.

The report also presents a detailed quantitative analysis of the current market trends and future estimations from 2017 to 2027.

The forecasts cover 3 Product Type, 3 Application Type, 3 End User Type, and 4 Regions.

• The study provides an in-depth analysis of the Global CRISPR-CAS9 Gene Editing Technologies Market with current trends and future estimations to elucidate investment pockets.

• Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.

• The report provides a quantitative analysis to help stakeholders capitalize on prevailing market opportunities from 2020 to 2027 in terms of value.

• Extensive analysis of different segments helps understand various products of the market.

• Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.

The report covers the following topics:

• Market Drivers, Restraints, and Opportunities

• Porters Five Forces Analysis

• Bargaining Power Of Buyers

• Bargaining Power Of Suppliers

• Threat of Substitutes

• Threat of a New Entrant

• Intensity Of Competitive Rivalry

• PESTEL analysis

• Top Winning Strategies, Top Investment Pockets

• Potential Venture Avenues

• Market Share Analysis

• Pipeline Analysis

• Regulatory Framework

• Cost Structure Analysis

• Top 15 Company Profiles, Product Portfolio, and Key Strategies

• COVID19 Impact on “CRISPR-CAS9 Gene Editing Technologies Market.